Novartis' Exelon To Be Reviewed By Advisory Cmte. May 17
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking approval for rivastigmine tartrate for the treatment of mild to moderate dementia associated with Parkinson's disease.